Welireg (belzutifan)

pCPA File Number: 22455

Negotiation Status:

Concluded with an LOI

Indication(s):

Von Hippel-Lindau (VHL) disease in adult patients who require therapy for associated non-metastatic renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or non-metastatic pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.

Sponsor/Manufacturer:

Merck Canada Inc.

CDA-AMC Project Number:

PC0309

pCPA Engagement Letter Issued:

2023-12-07

Negotiation Process Concluded:

2024-08-30